FDA Approves IMAAVY to Treat Warm Autoimmune Hemolytic Anemia
- By BSTQ Staff
The U.S. Food and Drug Administration (FDA) has approved IMAAVY (nipocalimab-aahu) to treat warm autoimmune hemolytic anemia (wAIHA), a rare, life-threatening autoantibody disease, in adults and pediatric patients 12 years of age and older currently or previously treated with corticosteroids. The approval, which follows FDA priority review, marks the first time a therapy was proven safe and effective specifically for the treatment of wAIHA.
Approval was based on the Phase II/III ENERGY study, which met its primary endpoint, a stringent endpoint definition that reflects meaningful increases in Hgb levels over time. The randomized, placebo-controlled trial demonstrated approximately three times as many patients receiving the approved dose of IMAAVY and achieved durable Hgb levels versus placebo by 24 weeks. Overall, patients in this treatment group showed a mean increase in Hgb of 1g/dL at week one. In addition, IMAAVY was associated with a 3.5-point higher mean FACIT-Fatigue score versus placebo at week 24, with higher scores defined as less fatigue. IMAAVY also demonstrated a safety profile consistent with the established safety profile of IMAAVY in generalized myasthenia gravis (gMG). The most common adverse reactions in patients with wAIHA treated with IMAAVY were peripheral edema, diarrhea and fever.
“Today’s announcement marks the second approval for IMAAVY and is an extraordinary milestone for people living with warm autoimmune hemolytic anemia, an underserved community that has waited far too long for an FDA-approved treatment,” said David M. Lee, MD, PhD, global immunology therapeutic area head at Johnson & Johnson. “As the first therapy approved for wAIHA, IMAAVY has the potential to redefine the management of wAIHA, particularly for those with uncontrolled disease. This milestone reinforces our motivation to continue pursuing advanced therapies for people living with allo- and autoantibody diseases like wAIHA.”
References
FDA Approves IMAAVY® (nipocalimab-aahu) as First-Ever Treatment for Warm Autoimmune Hemolytic Anemia (wAIHA), Representing a Landmark Advancement for Patients. Johnson & Johnson press release, Aug. 25, 2026.